Researchers ID Off-Target Protein-Kinase Binding Tied to HIV Drug's Cancer Efficacy

Based on a bioinformatic screen of roughly 6,000 human proteins, the scientists proposed that the anti-cancer effects of the HIV drug -- currently in clinical trials as a cancer treatment -- stem from weak binding to multiple protein kinases upstream of the PI3K/AKT signaling pathway.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.